Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

Ana M. Giménez‐Arnau(Universitat Autònoma de Barcelona), Thomas Murphy(Manchester Academic Health Science Centre), Maria‐Magdalena Balp(Novartis (Switzerland)), Theodore A. Omachi(University of California, San Francisco), Donald E. Stull(IQVIA (United States)), Sheldon L. Spector, Evgeniya Antonova, Karin Rosén(Baylor College of Medicine), Benjamin Trzaskoma(MDS Associates (United States))
Clinical and Translational Allergy
August 18, 2016
10.1186/s13601-016-0120-0
Cited by 34

Related Papers

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
|New England Journal of Medicine|2013|1.1k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
|Annals of Internal Medicine|2011|550